Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | BI 905711 |
Trade Name | |
Synonyms | BI-905711|BI905711 |
Drug Descriptions |
BI 905711 is a bispecific antibody that binds to and targets pro-apoptotic death receptor 5 (TRAILR2) and cadherin-17 (CDH17), potentially resulting in increased apoptosis in CDH17-positive tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C173541 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + BI 905711 + Fluorouracil + Irinotecan + Leucovorin | BI 905711 Bevacizumab Fluorouracil Irinotecan Leucovorin | 0 | 1 |
BI 905711 | BI 905711 | 0 | 1 |
BI 905711 + Fluorouracil + Irinotecan + Leucovorin | BI 905711 Fluorouracil Irinotecan Leucovorin | 0 | 1 |